Medicure Inc (MPH)

Currency in CAD
1.1500
0.0000(0.00%)
Closed·
MPH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
MPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.15001.1500
52 wk Range
0.63001.2700
Key Statistics
Bid/Ask
1.05 / 1.32
Prev. Close
1.15
Open
1.15
Day's Range
1.15-1.15
52 wk Range
0.63-1.27
Volume
-
Average Volume (3m)
3.52K
1-Year Change
9.52%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low revenue valuation multiple

Medicure Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Medicure Inc Company Profile

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Medicure Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue declined 3.5% to $5.5M, with a net loss of $694,000 ($0.07/share); stock unchanged at $0.94
  • ZYPITAMAG sales via Marley Drug up 17%; AGGRASTAT revenue down due to generic competition
  • Acquired Gateway Pharmacy; Phase 3 trial for MC1 ongoing; focus on growing ZYPITAMAG and expanding Marley Drug business
  • Cash position stable at $7.2M; Financial Health Score 'GREAT' (3.12/5) per InvestingPro analysis
  • CEO emphasizes business growth and revenue diversification; insurance coverage challenges for ZYPITAMAG noted
Last Updated: 22/05/2025, 14:00
Read Full Transcript

Compare MPH to Peers and Sector

Metrics to compare
MPH
Peers
Sector
Relationship
P/E Ratio
−6.7x−5.4x−0.5x
PEG Ratio
0.13−0.010.00
Price/Book
0.6x0.4x2.6x
Price / LTM Sales
0.6x2.2x3.3x
Upside (Analyst Target)
-153.9%41.6%
Fair Value Upside
Unlock11.5%5.9%Unlock

Earnings

Latest Release
May 21, 2025
EPS / Forecast
-0.07 / --
Revenue / Forecast
5.48M / --
EPS Revisions
Last 90 days

MPH Income Statement

FAQ

What Stock Exchange Does Medicure Trade On?

Medicure is listed and trades on the TSX Venture Exchange stock exchange.

What Is the Stock Symbol for Medicure?

The stock symbol for Medicure is "MPH."

What Is the Medicure Market Cap?

As of today, Medicure market cap is 12.00M.

What Is Medicure's Earnings Per Share (TTM)?

The Medicure EPS (TTM) is -0.17.

When Is the Next Medicure Earnings Date?

Medicure will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is MPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Medicure Stock Split?

Medicure has split 1 times.

How Many Employees Does Medicure Have?

Medicure has 38 employees.

What is the current trading status of Medicure (MPH)?

As of 13 Aug 2025, Medicure (MPH) is trading at a price of 1.15, with a previous close of 1.15. The stock has fluctuated within a day range of 1.15 to 1.15, while its 52-week range spans from 0.63 to 1.27.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.